Fate Therapeutics, Inc.
3535 General Atomics Court
Suite 200
San Diego
California
92121
United States
Website: http://www.fatetherapeutics.com/
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
105 articles with Fate Therapeutics, Inc.
-
Clinical Catch-Up: July 6-10
7/13/2020
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates. -
Clinical Catch-Up: May 18-22
5/26/2020
Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look. -
Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer.
-
Clinical Catch-Up: January 13-17
1/20/2020
There were plenty of clinical trial announcements this week. Here's a look. -
Clinical Catch-Up: September 2-8
9/9/2019
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting. -
Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies
9/19/2018
Option-based Collaboration to Develop Two CAR T-Cell Product Candidates Using Fate’s Proprietary iPSC Product Platform
-
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
-
Fate Therapeutics Announces First Patient Treated In Protmune PROTECT Clinical Trial For The Prevention Of Graft-Versus-Host Disease
1/5/2017
-
Fate Therapeutics To Webcast Conference Call Reporting Third Quarter 2016 Financial Results On November 7, 2016
11/1/2016
-
Fate Therapeutics Announces Issuance Of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions
10/5/2016
-
Fate Therapeutics Receives FDA Orphan Drug Designation For Protmune In Allogeneic Hematopoietic Cell Transplantation
9/26/2016
-
San Diego's Fate Therapeutics Lands a Deal With Star Scientist to Work on Off-the-Shelf T-Cell Immunotherapies
9/8/2016
-
Fate Therapeutics To Present At The 2016 Wedbush PacGrow Healthcare Conference
8/10/2016
-
Fate Therapeutics Reports Second Quarter 2016 Financial Results
8/9/2016
-
Fate Therapeutics Announces Issuance Of U.S. Patent On Compositions Of Human Induced Pluripotent Cells
7/26/2016
-
Fate Therapeutics Announces FDA Fast Track Designation For Protmune
6/20/2016
-
Fate Therapeutics To Host Off-The-Shelf Cancer Immunotherapy Focus Session At 2016 Annual Meeting Of International Society for Stem Cell Research
6/16/2016
-
Fate Therapeutics Appoints Chris M. Storgard, M.D. As Chief Medical Officer
5/17/2016
-
Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function Of Allogeneic Natural Killer Cell Cancer Immunotherapy
5/16/2016
-
Fate Therapeutics Reports First Quarter 2016 Financial Results
5/10/2016